New study tracks early lung disease in young smokers
NCT ID NCT04968249
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This study follows 200 adults aged 30-55 who smoke or have early COPD to learn how the disease progresses. Researchers will use breathing tests, symptom surveys, and CT scans to find early warning signs. The goal is to better understand risk factors and improve future care for COPD.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help identify early signs of COPD and risk factors, leading to better prevention or earlier treatment strategies.
- What could go wrong
- This is an observational study, not testing a treatment. It may not directly lead to new therapies, and results may not apply to all COPD patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
200 people
The number who actually took part.
- Started
-
Jul 2021
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients meeting inclusion criteria who have established disease as well as smokers meeting inclusion criteria where pulmonary function testing has not been performed.
- Ages
-
30 to 55 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * GOLD 0 Participant must be ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC ≥ 0.70 and FEV1 ≥ 80% predicted. * Preserved Ratio Impaired Spirometry (PRISm) participants shall be between ages 30-55 years; and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV150-79% predicted and FEV1/FVC \> 0.70. * GOLD 1 participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 \>= 80% predicted. OR * GOLD 2 participants shall be between ages 30-55 years, and have: ≥ 10 pack-year smoking history; post-bronchodilator FEV1/FVC \< 0.70 and FEV1 50-79% predicted. Exclusion Criteria: * Severe asthma, which is defined as any of the following: Current (i.e., at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS. or 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or One asthma hospitalization in the past 12 months * Concurrent participation in a therapeutic trial where treatment is blinded. * Active pregnancy at the time of the baseline or return visits. This special population is being excluded to minimize potential for fetal radiation exposure. * Cognitive dysfunction that prevents the participant from completing study procedures. * BMI \> 35.0 kg/m2 at baseline, due to the effects of body weight on CT scan imaging quality. * The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g., dyspnea or decreased exercise tolerance). * Any illness expected to cause mortality in the next 3 years. * Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan image quality. * History of thoracic radiation or thoracic surgery with resection of lung tissue
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Device-Preserved donor lungs boost transplant success?
- Tiny One-Way valves for emphysema under close watch in japan
- Is RSV a hidden driver of severe COPD attacks?
- Can Mountain-Air rehab loosen stiff COPD airways?
- Can a breath of extra oxygen boost lung rehab?
- Can a handheld breathing device and phone app help COPD patients breathe easier?